Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Carcinoma, Hepatocellular*/virology ; Carcinoma, Hepatocellular*/metabolism ; Carcinoma, Hepatocellular*/pathology ; Carcinoma, Hepatocellular*/genetics ; Carcinoma, Hepatocellular*/mortality ; CD24 Antigen*/metabolism ; CD24 Antigen*/genetics ; Liver Neoplasms*/virology ; Liver Neoplasms*/metabolism ; Liver Neoplasms*/pathology ; Liver Neoplasms*/genetics ; B7-H1 Antigen*/metabolism ; B7-H1 Antigen*/genetics ; CD47 Antigen*/metabolism ; CD47 Antigen*/genetics ; Hepatitis B virus*/genetics; Humans ; Male ; Female ; Middle Aged ; Prognosis ; Aged ; Adult ; Biomarkers, Tumor/metabolism ; Hepatitis B/complications ; Hepatitis B/virology ; Hepatitis B/metabolism ; Gene Expression Regulation, Neoplastic

Immune checkpoint inhibitor (ICI) therapy is the new standard treatment for advanced or metastatic hepatocellular carcinoma (HCC); however, many patients still fail to respond. This study explored the expression and prognosis of programmed death ligand 1 (PD-L1), cluster of differentiation 24 (CD24), and cluster of differentiation 47 (CD47) in patients with hepatitis B virus-associated HCC (HBV-associated HCC). We analyzed sequencing data from the Cancer Genome Atlas (TCGA) and investigated the expression of PD-L1, CD24, and CD47 in HBV-associated HCC patients by immunohistochemistry and their relationship with prognosis and clinicopathological factors. HCC data from the TCGA database show that PD-L1 was substantially correlated with various immune cells. In 67 patients with HBV-associated HCC, high PD-L1 and CD24 expression levels were related to poor overall survival (OS) and progression-free survival (PFS). PD-L1 expression was significantly associated with the staging of HBV-associated HCC (p = 0.011) and Ki67 expression (p = 0.024). Correlation analysis between variables reveals that PD-L1 was significantly positively correlated with CD24 and CD47. High expression of PD-L1 and CD24 are risk factors for poor prognosis in HBV-associated HCC patients following curative resection. PD-L1 is significantly correlated with CD24 and CD47.
Competing Interests: Declaration. Competing interests: The authors declare no competing interests. Institutional review board statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Fujian Provincial Hospital (Approval No. K2021-02-013).
(© 2024. The Author(s).)

Curr Gene Ther. 2020;20(2):109-126. (PMID: 32576128)
Cancer Cell Int. 2019 Jan 29;19:22. (PMID: 30718977)
J Cancer Res Clin Oncol. 2019 Feb;145(2):303-312. (PMID: 30267213)
N Engl J Med. 2019 Apr 11;380(15):1450-1462. (PMID: 30970190)
Int J Cancer. 2021 Feb 1;148(3):546-559. (PMID: 32790899)
Vaccines (Basel). 2020 Oct 19;8(4):. (PMID: 33086471)
Ann Surg. 2000 Jul;232(1):10-24. (PMID: 10862190)
Int J Biol Markers. 2021 Mar;36(1):54-61. (PMID: 33641486)
Cancer Res. 2019 Sep 15;79(18):4557-4566. (PMID: 31350295)
J Hepatol. 2020 Feb;72(2):250-261. (PMID: 31954490)
Oncology. 2017;92 Suppl 1:50-62. (PMID: 28147363)
J Clin Pathol. 2021 Feb;74(2):111-115. (PMID: 32576628)
Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1261-8. (PMID: 20447919)
Theranostics. 2021 Jan 19;11(7):3489-3501. (PMID: 33537099)
Trends Immunol. 2018 Mar;39(3):173-184. (PMID: 29336991)
Theranostics. 2019 Jul 9;9(16):4678-4687. (PMID: 31367249)
Immunity. 2007 Jul;27(1):111-22. (PMID: 17629517)
Front Immunol. 2022 Dec 19;13:1070961. (PMID: 36601120)
N Engl J Med. 1996 Mar 14;334(11):693-9. (PMID: 8594428)
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. (PMID: 34764464)
Ann Pathol. 2011 Nov;31(5 Suppl):S27-31. (PMID: 22054452)
J Natl Cancer Cent. 2023 Jul 15;3(3):186-196. (PMID: 39035191)
Inflamm Res. 2011 Jan;60(1):47-53. (PMID: 20661763)
Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059)
J Exp Med. 2001 Apr 2;193(7):855-62. (PMID: 11283158)
Breast. 2011 Feb;20(1):78-85. (PMID: 20810282)
Clin Cancer Res. 2009 Sep 1;15(17):5518-27. (PMID: 19706825)
Cancer Biol Med. 2023 Jan 12;20(1):. (PMID: 36647777)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Mol Cancer. 2022 Jan 21;21(1):28. (PMID: 35062949)
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543. (PMID: 33850328)
Chin J Cancer Res. 2018 Dec;30(6):571-579. (PMID: 30700925)
Nat Immunol. 2013 Oct;14(10):1014-22. (PMID: 24048123)

2023Y9327 Joint Funds for the innovation of science and Technology, Fujian Province; 2023Y9296 Joint Funds for the innovation of science and Technology, Fujian Province; 2022J01121025 Natural Science Foundation of Fujian Province

Keywords: CD24; CD47; HBV-associated hepatocellular carcinoma; Immune checkpoint inhibitors; PD-L1

0 (CD24 Antigen)
0 (B7-H1 Antigen)
0 (CD274 protein, human)
0 (CD47 Antigen)
0 (CD24 protein, human)
0 (CD47 protein, human)
0 (Biomarkers, Tumor)

Date Created: 20241229 Date Completed: 20241229 Latest Revision: 20250104

20250104

PMC11682133

10.1038/s41598-024-83145-5

39732950